What You Should Know:
– RedHill Biopharma, a specialty biopharmaceutical company, and ObvioHealth, a global virtual research organization, have partnered on the largest remote clinical study for a new at-home COVID-19 treatment, Upamostat.
– The trial is being performed completely remotely in patients’ homes using ObvioHealth’s clinical trial ecosystem including digital devices, a patient-centric smartphone application and home healthcare visits.
– The randomized, double-blind, placebo-controlled hybrid study will include more than 300 COVID-19-positive participants and evaluate the effectiveness of Upamostat against the virus. Patients are provided with Upamostat and five 510(k)-cleared devices to begin treatment while ObvioHealth’s platform collects both telemetric information and patient-reported information. Key remote safety monitoring includes patients’ heart rate, respiratory rate and temperature, which will be monitored continuously via a biosticker device, and their pulse oximetry, which is monitored twice daily.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
– Home healthcare nurses will make four in-home visits to check-in on patients, collect blood samples for certain laboratory parameters, perform virus PCR swabs at home, and assist in certain patient-reported data capture, using devices provided to participants at home.
